Kite, Forty Seven vets on board for launch of oncolytic virus start-up IconOVir with $77M series A

Developed by a Salk Institute team, the next-generation oncolytic virus technologies licensed by IconOVir have attracted a $77 million series A round from a seasoned investor syndicate and a president and CEO fresh off a multibillion-dollar deal in Mark McCamish.

San Diego-based IconOVir Bio Inc. is developing tumor-selective oncolytic viruses that can be administered intravenously rather than injected directly into tumors. Its platform comprises innovations developed in the lab of Salk professor Clodagh O’Shea, a scientific founder of the company...